GSK3B and breast carcinoma: We observed a similar effect by pharmacological GSK3B inhibition using SB216763 on PARPi sensitization in murine breast cancer cell 4T1 regardless of BRCA1 status (Supplemental Figure 9B) and BRCA1-proficient human breast cancer cells MCF7 (Supplemental Figure 9C).